Vaccines (Dec 2020)

Degradomics-Based Analysis of Tetanus Toxoids as a Quality Control Assay

  • Thomas J. M. Michiels,
  • Wichard Tilstra,
  • Martin R. J. Hamzink,
  • Justin W. de Ridder,
  • Maarten Danial,
  • Hugo D. Meiring,
  • Gideon F. A. Kersten,
  • Wim Jiskoot,
  • Bernard Metz

DOI
https://doi.org/10.3390/vaccines8040712
Journal volume & issue
Vol. 8, no. 4
p. 712

Abstract

Read online

Currently, batch release of toxoid vaccines, such as diphtheria and tetanus toxoid, requires animal tests to confirm safety and immunogenicity. Efforts are being made to replace these tests with in vitro assays in a consistency approach. Limitations of current in vitro assays include the need for reference antigens and most are only applicable to drug substance, not to the aluminum adjuvant-containing and often multivalent drug product. To overcome these issues, a new assay was developed based on mimicking the proteolytic degradation processes in antigen-presenting cells with recombinant cathepsin S, followed by absolute quantification of the formed peptides by liquid chromatography-mass spectrometry. Temperature-exposed tetanus toxoids from several manufacturers were used as aberrant samples and could easily be distinguished from the untreated controls by using the newly developed degradomics assay. Consistency of various batches of a single manufacturer could also be determined. Moreover, the assay was shown to be applicable to Al(OH)3 and AlPO4-adsorbed tetanus toxoids. Overall, the assay shows potential for use in both stability studies and as an alternative for in vivo potency studies by showing batch-to-batch consistency of bulk toxoids as well as for aluminum-containing vaccines.

Keywords